#clinicaldevelopment — Public Fediverse posts

https://www.europesays.com/dk/71219/ Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy #ATTRCM #ClinicalDevelopment #ClinicalTrial #FastTrackDesignation #HumanizedMonoclonalAntibody #NovoNordisk #ProthenaCorporationPlc

Asahi Kasei acquires German company Aicuris

Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company. The move comes after…
#Germany #DE #Europe #EU #Europa #AsahiKasei #biopharmaceuticalcompany #clinicaldevelopment #definitiveagreement #immunocompromisedpatients #issuedshares #pharmaceuticaltreatments #VeloxisPharmaceuticals
https://www.europesays.com/germany/6246/

Epicured Appoints Industry Veteran Patricia Bradley to Oversee Life Sciences Business https://www.byteseu.com/1496575/ #business #ClinicalDevelopment #ClinicalTrials #DIGITALHEALTH #DigitalSolutions #Epicured #EpicuredInc. #OverseeLifeSciences #PatriciaBradley #RichardBennett #SeniorVicePresident #TheCompany

https://www.europesays.com/dk/47190/ Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 #ClinicalDevelopment #Development #LexiconPharmaceuticals #MetabolicDisorders #MilestonePayment #NovoNordisk #Obesity #Phase1Study #PotentialDevelopment

https://www.europesays.com/ch/46706/ Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420 #Allschwil #AntibacterialProducts #AntimicrobialResistance #BacterialInfections #Basel #BasileaPharmaceutica #BiopharmaceuticalCompany #ClinicalDevelopment #ClinicalStudy #development #FungalInfections #NovelAntibiotic #ProductDevelopment #ResearchAndDevelopment #WorldHealthOrganization

https://www.europesays.com/ch/32453/ SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer’s Disease #Alzheimer'sDisease #AmyloidBeta #ClinicalDevelopment #CollaborationAgreement #commercialization #development #EarlyDevelopment #NeurodegenerativeDisease #Novartis #Pharmaceuticals #ProductDevelopment #ProprietaryTechnology #WorldwideLicense

https://www.europesays.com/ie/282589/ AstraZeneca to acquire Modella AI to speed oncology drug research #AI #AradhanaSarin #ArtificialIntelligence #ArtificialIntelligence #astrazeneca #BiomarkerDiscovery #ClinicalData #ClinicalDevelopment #Companies #Éire #IE #Ireland #Modella #Technology

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics, Inc. Robert Gagnon, CFO, Opus Genetics Robert Gagnon, CFO, Opus Genetics RESEARCH TRI…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Genetics #biopharmaceuticalcompany #ChiefExecutiveOfficer #ChiefFinancialOfficer #clinicaldevelopment #clinicalprograms #genetherapies #GeorgeMagrath #HarvardBioscience #retinaldiseases #RobGagnon #RobertGagnon #Science #strategicfinance
https://www.newsbeep.com/us/127237/

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics, Inc. Robert Gagnon, CFO, Opus Genetics Robert Gagnon, CFO, Opus Genetics RESEARCH TRI…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Genetics #biopharmaceuticalcompany #ChiefExecutiveOfficer #ChiefFinancialOfficer #clinicaldevelopment #clinicalprograms #genetherapies #GeorgeMagrath #HarvardBioscience #retinaldiseases #RobGagnon #RobertGagnon #Science #strategicfinance
https://www.newsbeep.com/us/127237/

Samsung Bioepis has promoted two Executive Vice Presidents and four Senior Vice Presidents in a performance-based leadership reshuffle, highlighting expertise in clinical development, manufacturing, regulatory affairs, and business strategy.
#YonhapInfomax #SamsungBioepis #ExecutivePromotion #Biosimilars #ClinicalDevelopment #BusinessStrategy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=92338

Samsung Bioepis has promoted two Executive Vice Presidents and four Senior Vice Presidents in a performance-based leadership reshuffle, highlighting expertise in clinical development, manufacturing, regulatory affairs, and business strategy.
#YonhapInfomax #SamsungBioepis #ExecutivePromotion #Biosimilars #ClinicalDevelopment #BusinessStrategy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=92338

Samsung Bioepis has promoted two Executive Vice Presidents and four Senior Vice Presidents in a performance-based leadership reshuffle, highlighting expertise in clinical development, manufacturing, regulatory affairs, and business strategy.
#YonhapInfomax #SamsungBioepis #ExecutivePromotion #Biosimilars #ClinicalDevelopment #BusinessStrategy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=92338

Samsung Bioepis has promoted two Executive Vice Presidents and four Senior Vice Presidents in a performance-based leadership reshuffle, highlighting expertise in clinical development, manufacturing, regulatory affairs, and business strategy.
#YonhapInfomax #SamsungBioepis #ExecutivePromotion #Biosimilars #ClinicalDevelopment #BusinessStrategy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=92338

https://www.europesays.com/uk/175096/ SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines #ClinicalDevelopment #EQTLifeSciences #GeneTherapy #GeneticMedicine #GeneticMedicines #GeneticMedicinesCompany #Genetics #ProteinSplicing #SanofiVentures #Science #SpliceBio #StargardtDisease #UK #UnitedKingdom #VentureFund

Clearmind Files South Korea Patent for MEAI in Depression https://www.byteseu.com/1514160/ #biotech #ClearmindMedicine #ClinicalDevelopment #CMND #CommercializationPlans #DepressionTreatment #GlobalIPPortfolio #IntellectualProperty #MEAI #MentalHealth #neuroplastogen #NonHallucinogenic #PatentFiling #SouthKorea #SouthKoreaPatent #WHO280Million